Kangfang Biology (09926.HK): The State Drug Administration accepted the marketing application for new indications of chetanil (cardonil, PD-1/CTLA-4) for first-line treatment of cervical cancer
Gelonghui, April 24 | Kang Fang Biotech (09926.HK) announced that the China Drug Administration (“NMPA”) has recently officially accepted the marketing application for a new indication (“SnDA”) for the first-line treatment of persistent, recurrent or metastatic cervical cancer with or without platinum-containing chemotherapy combined with or without bevacizumab, the world's first bispecific antibody (“NMPA”). Ketanil was approved by the NMPA in June 2022 to treat patients with recurrent or metastatic second-/third-line cervical cancer who have previously failed platinum-containing chemotherapy. This time s
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Hong Kong Stock Concept Tracking | Beijing introduces policies to support the high-quality development of innovative pharmaceuticals, institutions are optimistic about the rise of the domestic innovative drug industry chain (with concept stocks)
Various departments including the Beijing Municipal Medical Security Administration and the Beijing Drug Administration issued a number of measures to support the high-quality development of innovative medicines in Beijing
Is Akeso, Inc. (HKG:9926) Trading At A 47% Discount?
Key Insights The projected fair value for Akeso is HK$90.01 based on 2 Stage Free Cash Flow to Equity Current share price of HK$47.95 suggests Akeso is potentially 47% undervalued Analyst price t
[Broker Focus] CITIC Construction Investment maintains Kangfang Biotech's (09926) “buy” rating, indicating that the company's investment is expected to be realized at an accelerated pace in various fields
Jin Wu Financial News | According to CITIC Construction Investment Research Report, Kang Fang Biotech (09926) released first-line AK104 gastric cancer data at the AACR conference. The mid-term analysis yielded positive results: regardless of PD-L1 expression, the Cardonil combination regimen was significantly superior to chemotherapy. The company's 2024 recommendations focus on: (1) AK104 first-line cervical cancer NDA; (2) AK112 approved for marketing in China, head-to-head K drug data read, US completed enrollment, etc.; (3) PCSK9, IL12/23, etc. were approved for listing; (4) domestic NDAs and IL4R entry of the self-exempt drug IL17
Changes in Hong Kong stocks | Kangfang Biotech (09926) is now up more than 4%. Brilliant data on gastric cancer is expected to drive the evolution of gastric cancer treatment pattern
The Zhitong Finance App learned that Kang Fang Biotech (09926) is now up more than 4%. As of press release, it has risen 3.97% to HK$48.5, with a turnover of HK$125 million. According to the news, the positive analysis results of the phase III clinical study of Kangfang Biotech's core product, cardonil combined chemotherapy for first-line gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, were published in an oral report at the 2024 American Cancer Association Annual Meeting (AACR). The overall data was impressive. Guotai Junan pointed out that data shows that cardonil has the benefit advantage of the entire population and is expected to drive the evolution of gastric cancer treatment patterns. Currently on the front line of Cardonelli
Akeso to Raise Over HK$1 Billion Via Share Sale
Akeso (HKG:9926) has mandated Morgan Stanley Asia and CLSA to sell 24.8 million of its shares to no less than six placees at HK$47.65 apiece, according to a Thursday filing with the Hong Kong bourse.
[Broker Focus] Debon Securities maintains Kangfang Biotech's (09926) “buy” rating and is expected to enter a period of rapid performance growth in the next 2-3 years
Jinwu Financial News | According to Debon Securities Research, Kangfang Biotech (09926) recorded total revenue of 4,526 billion yuan in 2023, an increase of 440% over the previous year. Product sales in 2023 were $1,631 million (up 48% year over year), and the company confirmed annual technical licensing and technical cooperation revenue of about RMB 2,923 billion, mainly from the initial payment of the AK112, PD-1/VEGF (, PD-1/VEGF) license from Summit. Profit in 2023 was $1,942 million. According to the bank, the company invested a total of 1,254 billion yuan in R&D throughout the year. At the end of 2023,
Bank Rating | CMB International: Raised Kangfang Biotech's target price to HK$59.61, I believe this year will be another “good harvest year”
CMB International published a report raising the target price of Kangfang Biotech from HK$51.23 to HK$59.61, maintaining a “buy” rating. The company's revenue last year was 4.53 billion yuan, including product sales revenue of 1.63 billion yuan and license revenue related to AK112 of 2.92 billion yuan; product gross margin remained high at 91.8%, and the ratio of overall sales expenses to 56.3% of sales fell from 74.5% to 56.3%, reflecting improvements in operating efficiency. At the end of last year, it held sufficient cash of 4.9 billion yuan. The bank believes that this year is another “good harvest year”. Among them, AK104 and AK112 have potential for success and are not swollen
North Water Trends | Beishui Trading's net purchase of 4.772 billion Tencent (00700) announced a 100 billion HKD repurchase of domestic capital to raise over HK$1.6 billion
On March 21, in the Hong Kong stock market, Beishui had a net purchase of HK$4.772 billion, of which Hong Kong Stock Connect (Shanghai) had a net purchase of HK$1,628 billion and Hong Kong Stock Connect (Shenzhen) had a net purchase of HK$3.144 billion.
[Broker Focus] CITIC Construction Investment maintains Kangfang Biotech's (09926) “buy” rating, indicating that the development of oncological drugs and non-tumor drugs has fully entered the harvest period
Jinwu Financial News | According to CITIC Construction Investment Research and Development Report, Kang Fang Biotech (09926) released its 2023 performance report. During the reporting period, the company's total revenue reached a record high of 4,526 billion yuan, up 440.10% year on year; the sales amount in the innovative drug market reached a new high, reaching 1,631 billion yuan, up 47.74% year on year. Ketanil (cardonilizumab) boosted rapid sales performance growth; the company achieved a record high net profit of 1,942 billion yuan, turning a loss into a profit, the first annual profit since listing. The company's development of oncological drugs and non-tumor drugs has fully entered the harvest period, new mechanisms,
Kangfang Biotech is refinancing in the middle of the winter | Insight Research
What does refinancing $1.1 billion mean for existing shareholders?
Macquarie: The target price for Kangfang Biotech (09926)'s “Outperform the Market” rating was raised to HK$56
Macquarie expects Kang Fang Biotech (09926) to continue to profit from 2026, and is expected to be listed on the A-share market in 2025.
Morgan Stanley Acting as Placing Agent on Akeso Deal
Morgan Stanley Acting as Placing Agent on Akeso Deal
Kangfang Biotech (09926.HK): Placing 24.8 million new shares under a general mandate to raise approximately HK$1,182 billion
Gelonghui, March 21, 丨 Kang Fang Biotech (09926.HK) announced that on March 21, 2024, the company entered into a placement agreement with the placement agent (i.e. Morgan Stanley Asia Limited and CITIC Lyon Securities Limited). According to this, the company has agreed to place a total of 24.8 million shares to no less than six undertakers through the placement agent at a price of HK$47.65 per share. Placed shares are equivalent to about 2.95% of the company's current issued share capital and approximately 2.86% of the issued share capital was expanded immediately after the placement. Placed shares
Akers to Use Share Placement Proceeds for R&D, Meet Working Capital Needs
Akers to Use Share Placement Proceeds for R&D, Meet Working Capital Needs
Akeso Placing Shares at 6.02% Discount to Last Traded Price of HK$50.70/Share
Akeso Placing Shares at 6.02% Discount to Last Traded Price of HK$50.70/Share
Akeso Plans to Raise HK$1.17B in Net Proceeds From Share Placement
Akeso Plans to Raise HK$1.17B in Net Proceeds From Share Placement
Akeso Plans to Place 24.80M Shares for HK$47.65 Each
Akeso Plans to Place 24.80M Shares for HK$47.65 Each
No Data